Stay updated on T-DXd and Immunotherapy in HER2+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the T-DXd and Immunotherapy in HER2+ NSCLC Clinical Trial page.

Latest updates to the T-DXd and Immunotherapy in HER2+ NSCLC Clinical Trial page
- CheckyesterdayChange DetectedAdded Revision: v3.3.4 to the history and removed Revision: v3.3.3.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedAdded a new site revision entry, Revision: v3.3.3, to the history and removed HHS Vulnerability Disclosure and Revision: v3.3.2 from the footer.SummaryDifference0.1%

- Check51 days agoChange DetectedThe page header now displays Revision: v3.3.2, replacing Revision: v3.2.0.SummaryDifference0.1%

- Check58 days agoChange DetectedThe record history now shows new sections including Contacts/Locations, Eligibility, Arms and Interventions, Study Design, Study Description, and Study Status, expanding visibility of core trial details. A government funding notice was removed.SummaryDifference1.0%

- Check73 days agoChange DetectedOld and new screenshots show the same list of study record versions, with no additions or deletions to the study content; differences are only UI chrome in the Record History view. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check101 days agoChange DetectedUpdated operating status notice and version to v3.2.0; removes previous v3.1.0 reference and directs users to current status sources.SummaryDifference10%

Stay in the know with updates to T-DXd and Immunotherapy in HER2+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the T-DXd and Immunotherapy in HER2+ NSCLC Clinical Trial page.